Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04561102 · ClinicalTrials.gov registry record
Evaluation of the COVIDSeq Test in Nasal Swab and Saliva From a COVID-19 Asymptomatic Population
A clinical trial, sponsored by Illumina.
- Completed
- Registry status
- 644
- Enrollment target
NCT04561102 is a clinical trial that has completed, run by Illumina. The registered enrollment target is 644 participants.
The verdict
NCT04561102 has completed, sponsored by Illumina.
- COMPLETED
- Registry status
- 644 participants
- Enrollment target
Study Summary
"This is a prospective, single-center specimen collection study. Subjects 18 years of age or older who do not have symptoms of COVID-19 will be enrolled. Two nasal swab samples and one saliva sample will be collected from each subject. The saliva sample will be tested with the COVIDSeq Test and one nasal swab will be tested with an EUA approved COVID test. The other nasal swab sample will be stored and a subset (approximately 250 specimens) will be tested with the COVIDSeq Test. Results of all testing will be provided to the sponsor for statistical analysis. Results from the comparator EUA test will be provided to the collection site investigator or designated collection site study staff. No medical treatment, guidance on treatment decisions, nor medical care will be provided. "
Interventions
- DIAGNOSTIC_TEST Diagnostic test for detection of SARS-CoV-2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 644 participants |
| Start Date | 2020-09-11 |
| Est. Completion | 2021-02-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04561102
The ClinicalTrials.gov registry entry for NCT04561102 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 644 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Illumina, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Diagnostic test for detection of SARS-CoV-2 is the first listed.
NCT04561102 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04561102 about?
NCT04561102 is a clinical study titled "Evaluation of the COVIDSeq Test in Nasal Swab and Saliva From a COVID-19 Asymptomatic Population". "This is a prospective, single-center specimen collection study. Subjects 18 years of age or older who do not have symptoms of COVID-19 will be enrolled. Two nasal swab samples and one saliva sample will be collected from each subject. The saliva sample will be tested with the COVIDSeq Test and one ...
What is the current status of trial NCT04561102?
This trial is currently completed. The enrollment target is 644 participants. The study started on 2020-09-11. Estimated completion is 2021-02-28.
What interventions are being tested in trial NCT04561102?
The interventions under investigation include: Diagnostic test for detection of SARS-CoV-2 (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04561102?
This trial is sponsored by Illumina, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.